A Determination of Pan-pathogen Antimicrobials?

Overview

Journal Med Drug Discov

Date 2022 Jan 31

PMID 35098103

Authors

Praveen Prathapan

Affiliations

Soon will be listed here.

Abstract

While antimicrobial drug development has historically mitigated infectious diseases that are known, COVID-19 revealed a dearth of 'in-advance' therapeutics suitable for infections by pathogens that have not yet emerged. Such drugs must exhibit a property that is antithetical to the classical paradigm of antimicrobial development: the ability to treat infections by any pathogen. Characterisation of such 'pan-pathogen' antimicrobials requires consolidation of drug repositioning studies, a new and growing field of drug discovery. In this review, a previously-established system for evaluating repositioning studies is used to highlight 4 therapeutics which exhibit pan-pathogen properties, namely azithromycin, ivermectin, niclosamide, and nitazoxanide. Recognition of the pan-pathogen nature of these antimicrobials is the cornerstone of a novel paradigm of antimicrobial development that is not only anticipatory of pandemics and bioterrorist attacks, but cognisant of conserved anti-infective mechanisms within the host-pathogen interactome which are only now beginning to emerge. Ultimately, the discovery of pan-pathogen antimicrobials is concomitantly the discovery of a new class of antivirals, and begets significant implications for pandemic preparedness research in a world after COVID-19.

Citing Articles

Superior Anticancer and Antifungal Activities of New Sulfanyl-Substituted Niclosamide Derivatives.

Ma J, Veeragoni D, Ghosh H, Mutter N, Barbosa G, Webster L Biomedicines. 2024; 12(7).

PMID: 39062194 PMC: 11275179. DOI: 10.3390/biomedicines12071621.

The African Kelleni's roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one.

Kelleni M Inflammopharmacology. 2023; 31(6):3335-3338.

PMID: 37326756 PMC: 10691980. DOI: 10.1007/s10787-023-01263-4.

References

Christian Perez J, Kumamoto C, Johnson A . Candida albicans commensalism and pathogenicity are intertwined traits directed by a tightly knit transcriptional regulatory circuit. PLoS Biol. 2013; 11(3):e1001510. PMC: 3601966. DOI: 10.1371/journal.pbio.1001510. View

Tauber S, Nau R . Immunomodulatory properties of antibiotics. Curr Mol Pharmacol. 2009; 1(1):68-79. View

Ghasemnejad-Berenji M, Pashapour S . SARS-CoV-2 and the Possible Role of Raf/MEK/ERK Pathway in Viral Survival: Is This a Potential Therapeutic Strategy for COVID-19?. Pharmacology. 2020; 106(1-2):119-122. PMC: 7573895. DOI: 10.1159/000511280. View

Wang Q, Nie Q, Feng Z . RNA interference: antiviral weapon and beyond. World J Gastroenterol. 2003; 9(8):1657-61. PMC: 4611519. DOI: 10.3748/wjg.v9.i8.1657. View

Check Hayden E . Biodefence since 9/11: The price of protection. Nature. 2011; 477(7363):150-2. DOI: 10.1038/477150a. View

MCNAUGHT W . Limitations of the germ theory. Lancet. 1968; 2(7561):220. DOI: 10.1016/s0140-6736(68)92655-x. View

Rajamuthiah R, Fuchs B, Conery A, Kim W, Jayamani E, Kwon B . Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS One. 2015; 10(4):e0124595. PMC: 4405337. DOI: 10.1371/journal.pone.0124595. View

Heaton S . Harnessing host-virus evolution in antiviral therapy and immunotherapy. Clin Transl Immunology. 2019; 8(7):e1067. PMC: 6613463. DOI: 10.1002/cti2.1067. View

Pieters V, Co I, Wu N, McGuigan A . Applications of Omics Technologies for Three-Dimensional Disease Models. Tissue Eng Part C Methods. 2021; 27(3):183-199. DOI: 10.1089/ten.TEC.2020.0300. View

10.

Banjanac M, Munic Kos V, Nujic K, Vrancic M, Belamaric D, Crnkovic S . Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells. Pharmacol Res. 2012; 66(4):357-62. DOI: 10.1016/j.phrs.2012.06.011. View

11.

Ahn J, Barber G . STING signaling and host defense against microbial infection. Exp Mol Med. 2019; 51(12):1-10. PMC: 6906460. DOI: 10.1038/s12276-019-0333-0. View

12.

DuShane J, Maginnis M . Human DNA Virus Exploitation of the MAPK-ERK Cascade. Int J Mol Sci. 2019; 20(14). PMC: 6679023. DOI: 10.3390/ijms20143427. View

13.

MAYNARD R, Tetley T . Bioterrorism: the lung under attack. Thorax. 2004; 59(3):188-9. PMC: 1746961. DOI: 10.1136/thx.2003.016659. View

14.

Rajter J, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter J . Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2020; 159(1):85-92. PMC: 7550891. DOI: 10.1016/j.chest.2020.10.009. View

15.

Baxter A . Louis Pasteur's beer of revenge. Nat Rev Immunol. 2002; 1(3):229-32. DOI: 10.1038/35105083. View

16.

Sam Q, Yew W, Seneviratne C, Chang M, Chai L . Immunomodulation as Therapy for Fungal Infection: Are We Closer?. Front Microbiol. 2018; 9:1612. PMC: 6068232. DOI: 10.3389/fmicb.2018.01612. View

17.

Lee N, Wong C, Chan M, Yeung E, Tam W, Tsang O . Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. Antiviral Res. 2017; 144:48-56. DOI: 10.1016/j.antiviral.2017.05.008. View

18.

Jensen C, Teng Y . Is It Time to Start Transitioning From 2D to 3D Cell Culture?. Front Mol Biosci. 2020; 7:33. PMC: 7067892. DOI: 10.3389/fmolb.2020.00033. View

19.

Mihara T, Nishimura Y, Shimizu Y, Nishiyama H, Yoshikawa G, Uehara H . Linking Virus Genomes with Host Taxonomy. Viruses. 2016; 8(3):66. PMC: 4810256. DOI: 10.3390/v8030066. View

20.

Pirofski L, Casadevall A . Immunomodulators as an antimicrobial tool. Curr Opin Microbiol. 2006; 9(5):489-95. PMC: 7108246. DOI: 10.1016/j.mib.2006.08.004. View